Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

IMPORTANCE: Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown. OBJECTIVE: To determine the efficacy of 5 or 10 days of remdesivir treatment compared with stan...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA
Hlavní autoři: Spinner, Christoph D., Gottlieb, Robert L., Criner, Gerard J., Arribas López, José Ramón, Cattelan, Anna Maria, Soriano Viladomiu, Alex, Ogbuagu, Onyema, Malhotra, Prashant, Mullane, Kathleen M., Castagna, Antonella, Chai, Louis Yi Ann, Roestenberg, Meta, Tsang, Owen Tak Yin, Bernasconi, Enos, Le Turnier, Paul, Chang, Shan-Chwen, SenGupta, Devi, Hyland, Robert H., Osinusi, Anu O., Cao, Huyen, Blair, Christiana, Wang, Hongyuan, Gaggar, Anuj, Brainard, Diana M., McPhail, Mark J., Bhagani, Sanjay, Ahn, Mi Young, Sanyal, Arun J., Huhn, Gregory, Marty, Francisco M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2020
Témata:
Original Investigation
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7442954/
https://ncbi.nlm.nih.gov/pubmed/32821939
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2020.16349
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky